Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability of AZD4547 in Patients With Solid Tumors and Its Efficacy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma With FGFR2/3 Gene Alterations

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability of AZD4547 in Patients With Solid Tumors and Its Efficacy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma With FGFR2/3 Gene Alterations

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbisko Therapeutics

    • Most Recent Events

    • 29 Apr 2021 According to an Abbisko Therapeutics media release, this trial will be initiated soon.
    • 01 Jan 2021 New trial record
    • 14 Dec 2020 According to an Abbisko Therapeutics media release, the company has obtained IND approval of ABSK091 (AZD4547), by National Medical Products Administration (NMPA) of China, and will initiate this phase Ib/II clinical study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top